Docality.com Logo
 
Dr. Fabio  Volterra  Md image

Dr. Fabio Volterra Md

2330 Eastchester Rd
Bronx NY 10469
718 324-4000
Medical School: Other - 1983
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: No
License #: 190793
NPI: 1841289931
Taxonomy Codes:
174400000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Fabio Volterra is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$510.42 Average Price Allowed
By Medicare:
$120.69
HCPCS Code:38221 Description:Bone marrow biopsy Average Price:$576.70 Average Price Allowed
By Medicare:
$193.93
HCPCS Code:96413 Description:Chemo iv infusion 1 hr Average Price:$530.53 Average Price Allowed
By Medicare:
$159.41
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$355.60 Average Price Allowed
By Medicare:
$158.94
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$263.53 Average Price Allowed
By Medicare:
$118.69
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$178.65 Average Price Allowed
By Medicare:
$77.48
HCPCS Code:96367 Description:Tx/proph/dg addl seq iv inf Average Price:$125.70 Average Price Allowed
By Medicare:
$38.21
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$59.15 Average Price Allowed
By Medicare:
$28.42
HCPCS Code:85025 Description:Complete cbc w/auto diff wbc Average Price:$30.00 Average Price Allowed
By Medicare:
$11.02
HCPCS Code:96365 Description:Ther/proph/diag iv inf init Average Price:$98.86 Average Price Allowed
By Medicare:
$86.94
HCPCS Code:36415 Description:Routine venipuncture Average Price:$10.00 Average Price Allowed
By Medicare:
$3.00

HCPCS Code Definitions

99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
96413
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96367
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)
38221
Bone marrow; biopsy, needle or trocar
99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
96365
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1184624165
Internal Medicine
610
1891888046
Diagnostic Radiology
531
1851379911
Internal Medicine
519
1205894268
Hematology/Oncology
471
1871517177
Vascular Surgery
435
1518956614
Hematology/Oncology
371
1790881852
Diagnostic Radiology
294
1225074941
General Surgery
273
1588695522
Nuclear Medicine
226
1477552065
Diagnostic Radiology
218
*These referrals represent the top 10 that Dr. Volterra has made to other doctors

Publications

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. - Investigational new drugs
GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM231 is combined with docetaxel. This trial assesses the safety of this combination.Docetaxel was administered once every three weeks (one-cycle) at doses between 50-75 mg/m2. GEM231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks.Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50-75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)--grade-3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p<0.001]; however, there were no hemorrhagic episodes.The recommended dose for further development of the combination of docetaxel and GEM231 is 75 mg/m2 and 220 mg/m2, respectively. It is important to administer GEM231 twice weekly for 2 consecutive weeks followed by a one-week break.
A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. - Investigational new drugs
The analog, rebeccamycin tartrate salt (NSC 655649, Cancer Therapy Evaluation Program, National Cancer Institute) has broad preclinical anti-neoplastic activity. Preliminary data from phase I study demonstrated antitumor activity in colorectal carcinoma. This phase II trial evaluates its efficacy in patients with minimally treated metastatic colorectal cancer. Eligibility included Karnofsky performance status > or = 70%, age > or = 18 years and bidimensionally measurable disease. Thirteen patients were treated with NSC 655649 at 500 mg/m2 by central venous catheter once every 3 weeks by bolus injection. Thirty-four cycles (median [range] 2 [1-6]) of therapy were administered. Twelve patients are eligible for response assessment. No major objective responses were seen using the RECIST criteria; however stable disease was observed in three patients with mean duration of 15 weeks. The median time to progression was 8 weeks. There was no toxic death. Four patients received only one cycle of treatment, and three had disease progression. Toxicities were tolerable and hematologic toxicity was the most common. The median (range) granulocyte and platelet nadir counts were 2043/microl (116-16,374/microl) and 276 x 10(3)/ microl (5-769), respectively. Non-hematologic toxicities were moderate, including generalized weakness/fatigue, nausea/vomiting, diarrhea and anorexia. One patient required dose reduction; three patients required dose delays. NSC 655649 at this dose and schedule is inactive against advanced previously minimally treated metastatic colorectal cancer and further study of this drug as a single agent in this disease using an every three-week schedule is not warranted.
Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia. - Cancer investigation
Intracaval and intracardiac nonseminomatous germ cell tumor metastases although rare have been previously reported in the literature. Most cases arise as a result of direct hematogenous spread via invasion of the internal spermatic vein, or from lymphatic venous shunting. We report a unique case of disseminated testicular germ cell tumor that presented with extensive intracaval and intracardiac metastatic teratoma and with valvular involvement. These findings were heralded by the presence of a new cardiac murmur, anemia, and severe thrombocytopenia. Resection of the intracardiac mass, prompted by rapid tumor progression despite treatment with systemic chemotherapy, demonstrated mature teratoma and resulted in prompt normalization of the patients hematologic profile.

Map & Directions

2330 Eastchester Rd Bronx, NY 10469
View Directions In Google Maps

Nearby Doctors

2225 Lodovick Ave
Bronx, NY 10469
718 557-7700
2426 Eastchester Rd Ste 204
Bronx, NY 10469
718 316-6547
2330 Eastchester Road
Bronx, NY 10469
718 324-4051
1500 Astor Ave Montefiore Medical Group-2Nd Floor
Bronx, NY 10469
718 810-0100
2741 Fenton Ave
Bronx, NY 10469
718 065-5757
2505 Williamsbridge Road
Bronx, NY 10469
718 542-2320
3448 Boston Rd Williamsbridge Family Practice Center
Bronx, NY 10469
718 476-6111
2316 Bruner Ave
Bronx, NY 10469
718 522-2461
3455 Boston Rd
Bronx, NY 10469
718 982-2236
3229 Tenbroeck Ave Apt.1
Bronx, NY 10469
336 536-6336